Premium
THE PREDICTION OF RELAPSE AFTER DRUG TREATMENT OF GRAVES' DISEASE BY ASSAY OF LONG ACTING THYROID STIMULATOR‐PROTECTOR (LATS‐P)
Author(s) -
HARDISTY C. A.,
HANFORD LINDA,
MUNRO D. S.
Publication year - 1981
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1981.tb00640.x
Subject(s) - medicine , graves' disease , antithyroid drugs , endocrinology , drug , disease , thyroid , antithyroid agent , pharmacology
SUMMARY In a study of fifty‐two patients with Graves' disease followed for 1 year after stopping antithyroid drugs, a strong relationship has been found between serum LATS‐P and relapse. In those with serum LATS‐P activity on stopping therapy, twenty‐one (88%) out of twenty‐four relapsed. In those with no LATS‐P activity on stopping antithyroid drugs only eight (29%) out of twenty‐eight relapsed and in five LATS‐P was detectable at relapse. The overall prevalence of positive assays for LATS‐P at relapse (90%) was similar to that seen in untreated Graves' disease.